Mouse CCL9 Chemokine Acts as Tumor Suppressor in a Murine Model of Colon Cancer

Colorectal cancer is the third most frequently diagnosed cancer in the world. Despite extensive studies and apparent progress in modern strategies for disease control, the treatment options are still not sufficient and effective, mostly due to frequently encountered resistance to immunotherapy of colon cancer patients in common clinical practice. In our study, we aimed to uncover the CCL9 chemokine action employing the murine model of colon cancer to seek new, potential molecular targets that could be promising in the development of colon cancer therapy. Mouse CT26.CL25 colon cancer cell line was used for introducing lentivirus-mediated CCL9 overexpression. The blank control cell line contained an empty vector, while the cell line marked as CCL9+ carried the CCL9-overexpressing vector. Next, cancer cells with empty vector (control) or CCL9-overexpressing cells were injected subcutaneously, and the growing tumors were measured within 2 weeks. Surprisingly, CCL9 contributed to a decline in tumor growth in vivo but had no effect on CT26.CL25 cell proliferation or migration in vitro. Microarray analysis of the collected tumor tissues revealed upregulation of the immune system-related genes in the CCL9 group. Obtained results suggest that CCL9 reveals its anti-proliferative functions by interplay with host immune cells and mediators that were absent in the isolated, in vitro system. Under specific study conditions, we determined unknown features of the murine CCL9 that have so far bee reported to be predominantly pro-oncogenic.

[1]  Tal Danino,et al.  Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity , 2023, Science advances.

[2]  J. Bibb,et al.  RORγt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic Colitis , 2022, The Journal of Immunology.

[3]  Michel-Edwar Mickael,et al.  RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells , 2021, The Journal of Immunology.

[4]  Z. Ju,et al.  Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation , 2021, Signal Transduction and Targeted Therapy.

[5]  B. Schaar,et al.  Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1 , 2020, Communications biology.

[6]  G. Manda,et al.  Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease , 2020, Pharmaceutics.

[7]  Michel-Edwar Mickael,et al.  "Retinoid-related orphan receptor RORγt in CD4+T cell-mediated intestinal homeostasis and inflammation." , 2020, The American journal of pathology.

[8]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[9]  E. Hays,et al.  Cell-mediated immune resistance in cancer , 2020, Cancer drug resistance.

[10]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[11]  Z. Gaciong,et al.  Effect of Chemokine (C-C Motif) Ligand 7 (CCL7) and Its Receptor (CCR2) Expression on Colorectal Cancer Behaviors , 2019, International journal of molecular sciences.

[12]  Ruibin Xi,et al.  CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma , 2018, Hepatology.

[13]  J. Bautista,et al.  A role for Th1‐like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders , 2019, Molecular immunology.

[14]  Denis Torre,et al.  BioJupies: Automated Generation of Interactive Notebooks for RNA-Seq Data Analysis in the Cloud. , 2018, Cell systems.

[15]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[16]  S. Rose-John,et al.  Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis , 2017 .

[17]  Ke Chen,et al.  Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway , 2017, Cell Death and Disease.

[18]  Jannetta S. Steyn,et al.  An optimised phylogenetic method sheds more light on the main branching events of rhodopsin-like superfamily. , 2016, Comparative biochemistry and physiology. Part D, Genomics & proteomics.

[19]  A. Korman,et al.  Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology , 2016, PloS one.

[20]  A. Korman,et al.  Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology , 2016, PloS one.

[21]  M. Omar Din,et al.  Synchronized cycles of bacterial lysis for in vivo delivery , 2016, Nature.

[22]  L. Terracciano,et al.  Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer , 2015, Gut.

[23]  K. Hunter,et al.  CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. , 2015, Cancer research.

[24]  L. Coussens,et al.  Duality of the immune response in cancer: lessons learned from skin. , 2014, The Journal of investigative dermatology.

[25]  T. Masaki,et al.  Expression profiles of 507 proteins from a biotin label-based antibody array in human colorectal cancer. , 2014, Oncology reports.

[26]  E. Hatano,et al.  Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. , 2013, Gastroenterology.

[27]  T. Miyasho,et al.  The neutrophil elastase inhibitor sivelestat suppresses accelerated gastrointestinal tumor growth via peritonitis after cecal ligation and puncture. , 2013, Anticancer research.

[28]  H. Guo,et al.  Identification of serum CCL15 in hepatocellular carcinoma , 2013, British Journal of Cancer.

[29]  Richard Bonneau,et al.  A Validated Regulatory Network for Th17 Cell Specification , 2012, Cell.

[30]  E. Mohit,et al.  Chemokine-based immunotherapy: delivery systems and combination therapies. , 2012, Immunotherapy.

[31]  D. Mager,et al.  Human Th1 and Th17 Cells Exhibit Epigenetic Stability at Signature Cytokine and Transcription Factor Loci , 2011, The Journal of Immunology.

[32]  E. El-Omar,et al.  The Inflammatory Microenvironment in Colorectal Neoplasia , 2011, PloS one.

[33]  A. Aman,et al.  Cell migration during morphogenesis. , 2010, Developmental biology.

[34]  A. Chapoval,et al.  Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis , 2009, The British journal of dermatology.

[35]  J. Weiss,et al.  Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment , 2009, Proceedings of the National Academy of Sciences.

[36]  D. Cho,et al.  Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. , 2009, Oncology reports.

[37]  G. Daley,et al.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. , 2009, Blood.

[38]  John Calvin Reed,et al.  Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth , 2009, Cancer Immunology, Immunotherapy.

[39]  G. Iotti,et al.  Expression of CCL9/MIP-1γ is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells , 2007, Oncogene.

[40]  N. Minato,et al.  SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion , 2007, Nature Genetics.

[41]  I. Pastan,et al.  Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[42]  B. Premack,et al.  Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 , 2005, The Journal of Immunology.

[43]  L. Gardner,et al.  Leukocyte extravasation: chemokine transport and presentation by the endothelium. , 2002, Blood.

[44]  J. Prieto,et al.  In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity , 2000, Gene Therapy.

[45]  B. Beutler,et al.  MIP-1γ : molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo , 1995 .